Stryker Corporation (SYK) EV/Sales Ratio: 5.24x
Is Stryker Corporation’s EV/Sales ratio high or low?
Stryker Corporation's EV/Sales ratio of 5.24x is 19% below its 5-year average of 6.45x, near the low end of its 5-year range (4.81x–7.73x).
As of Wednesday, June 17, 2026. 16.57% below its 12-month average of 6.28x.
SYK EV/Sales Ratio Chart
SYK Average EV/Sales Ratio Chart
SYK Current vs Average EV/Sales Ratio Chart
SYK EV/Sales Ratio Metrics
EV/SALES RATIO
5.24x
EV/SALES RATIO AVG TTM
6.28x
EV/SALES RATIO AVG 3Y
6.61x
EV/SALES RATIO AVG 5Y
6.45x
EV/SALES RATIO AVG 10Y
5.98x
EV/SALES RATIO AVG 15Y
5.07x
EV/SALES RATIO AVG 20Y
4.70x
CURRENT VS TTM AVG
-16.57%
CURRENT VS 3Y AVG
-20.73%
CURRENT VS 5Y AVG
-18.74%
CURRENT VS 10Y AVG
-12.31%
CURRENT VS 15Y AVG
+3.39%
CURRENT VS 20Y AVG
+11.54%
SYK Competitors' EV/Sales Ratio
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Stryker Corporation (SYK) | $119.06B | 5.24x | 6.28x | 6.61x | 6.45x |
| Bristol-Myers Squibb Company (BMY)vs › | $114.38B | 3.09x | 2.99x | 3.12x | 3.47x |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $113.82B | 9.13x | 9.42x | 10.00x | 9.07x |
| CVS Health Corporation (CVS)vs › | $127.54B | 0.48x | 0.44x | 0.43x | 0.51x |
| Danaher Corporation (DHR)vs › | $128.72B | 5.71x | 6.61x | 7.16x | 6.99x |
| Medtronic plc (MDT)vs › | $104.05B | 3.44x | 4.21x | 4.19x | 4.55x |
| Intuitive Surgical, Inc. (ISRG)vs › | $148.26B | 13.97x | 18.33x | 19.51x | 18.67x |
| Pfizer Inc. (PFE)vs › | $148.76B | 3.34x | 3.30x | 3.43x | 3.63x |
| HCA Healthcare, Inc. (HCA)vs › | $88.05B | 1.82x | 2.05x | 1.95x | 1.92x |
| Elevance Health Inc. (ELV)vs › | $86.74B | 0.55x | 0.51x | 0.67x | 0.76x |
Understanding EV/Sales
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
- It works for unprofitable companies where P/E doesn't apply
- Revenue is harder to manipulate than earnings
- It supports comparisons across companies at different profitability stages
- It is frequently used for software and other revenue-growth-focused companies
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
Stryker Corporation EV/Sales Ratio Formula & Definition
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Stryker Corporation EV/Sales Ratio FAQ
- What is the EV/Sales ratio for Stryker Corporation (SYK)?
- The EV/Sales ratio for SYK stock is 5.24x.
- Is Stryker Corporation's EV/Sales ratio high or low?
- Stryker Corporation's EV/Sales ratio of 5.24x is 19% below its 5-year average of 6.45x, near the low end of its 5-year range (4.81x–7.73x).
- What is the TTM average EV/Sales ratio for Stryker Corporation (SYK)?
- The TTM average EV/Sales ratio for SYK stock is 6.28x.
- What is the 3Y average EV/Sales ratio for Stryker Corporation (SYK)?
- The 3Y average EV/Sales ratio for SYK stock is 6.61x.
- What is the 5Y average EV/Sales ratio for Stryker Corporation (SYK)?
- The 5Y average EV/Sales ratio for SYK stock is 6.45x.
- What is the 10Y average EV/Sales ratio for Stryker Corporation (SYK)?
- The 10Y average EV/Sales ratio for SYK stock is 5.98x.
- What is the 15Y average EV/Sales ratio for Stryker Corporation (SYK)?
- The 15Y average EV/Sales ratio for SYK stock is 5.07x.
- What is the 20Y average EV/Sales ratio for Stryker Corporation (SYK)?
- The 20Y average EV/Sales ratio for SYK stock is 4.70x.
Stryker Corporation EV/Sales Ratio History
| DATE | EV/SALES RATIO |
|---|---|
| 2026-06-16 | 5.24x |
| 2026-06-15 | 5.20x |
| 2026-06-12 | 5.26x |
| 2026-06-11 | 5.16x |
| 2026-06-10 | 5.21x |
| 2026-06-09 | 5.29x |
| 2026-06-08 | 5.10x |
| 2026-06-05 | 5.16x |
| 2026-06-04 | 5.10x |
| 2026-06-03 | 5.00x |
| 2026-06-02 | 4.97x |
| 2026-06-01 | 5.07x |
| 2026-05-29 | 5.16x |
| 2026-05-28 | 5.19x |
| 2026-05-27 | 5.17x |
| 2026-05-26 | 5.28x |
| 2026-05-22 | 5.33x |
| 2026-05-21 | 5.28x |
| 2026-05-20 | 5.41x |
| 2026-05-19 | 5.35x |
| 2026-05-18 | 5.28x |
| 2026-05-15 | 5.18x |
| 2026-05-14 | 5.16x |
| 2026-05-13 | 5.11x |
| 2026-05-12 | 4.99x |
| 2026-05-11 | 4.81x |
| 2026-05-08 | 4.88x |
| 2026-05-07 | 5.02x |
| 2026-05-06 | 4.99x |
| 2026-05-05 | 5.04x |
| 2026-05-04 | 4.97x |
| 2026-05-01 | 5.03x |
| 2026-04-30 | 5.34x |
| 2026-04-29 | 5.34x |
| 2026-04-28 | 5.44x |
| 2026-04-27 | 5.55x |
| 2026-04-24 | 5.53x |
| 2026-04-23 | 5.56x |
| 2026-04-22 | 5.56x |
| 2026-04-21 | 5.53x |
| 2026-04-20 | 5.70x |
| 2026-04-17 | 5.77x |
| 2026-04-16 | 5.70x |
| 2026-04-15 | 5.74x |
| 2026-04-14 | 5.81x |
| 2026-04-13 | 5.84x |
| 2026-04-10 | 5.71x |
| 2026-04-09 | 5.71x |
| 2026-04-08 | 5.72x |
| 2026-04-07 | 5.60x |
| 2026-04-06 | 5.61x |
| 2026-04-02 | 5.59x |
| 2026-04-01 | 5.56x |
| 2026-03-31 | 5.55x |
| 2026-03-30 | 5.51x |
| 2026-03-27 | 5.53x |
| 2026-03-26 | 5.61x |
| 2026-03-25 | 5.53x |
| 2026-03-24 | 5.55x |
| 2026-03-23 | 5.61x |
| 2026-03-20 | 5.66x |
| 2026-03-19 | 5.72x |
| 2026-03-18 | 5.81x |
| 2026-03-17 | 5.86x |
| 2026-03-16 | 5.87x |
| 2026-03-13 | 5.67x |
| 2026-03-12 | 5.68x |
| 2026-03-11 | 5.81x |
| 2026-03-10 | 6.01x |
| 2026-03-09 | 6.12x |
| 2026-03-06 | 6.10x |
| 2026-03-05 | 6.19x |
| 2026-03-04 | 6.37x |
| 2026-03-03 | 6.41x |
| 2026-03-02 | 6.45x |
| 2026-02-27 | 6.45x |
| 2026-02-26 | 6.43x |
| 2026-02-25 | 6.40x |
| 2026-02-24 | 6.36x |
| 2026-02-23 | 6.41x |
| 2026-02-20 | 6.34x |
| 2026-02-19 | 6.23x |
| 2026-02-18 | 6.30x |
| 2026-02-17 | 6.17x |
| 2026-02-13 | 6.12x |
| 2026-02-12 | 6.12x |
| 2026-02-11 | 6.09x |
| 2026-02-10 | 6.31x |
| 2026-02-09 | 6.23x |
| 2026-02-06 | 6.27x |
| 2026-02-05 | 6.33x |
| 2026-02-04 | 6.30x |
| 2026-02-03 | 6.31x |
| 2026-02-02 | 6.42x |
| 2026-01-30 | 6.45x |
| 2026-01-29 | 6.20x |
| 2026-01-28 | 6.26x |
| 2026-01-27 | 6.21x |
| 2026-01-26 | 6.25x |
| 2026-01-23 | 6.22x |
| 2026-01-22 | 6.27x |
| 2026-01-21 | 6.34x |
| 2026-01-20 | 6.29x |
| 2026-01-16 | 6.35x |
| 2026-01-15 | 6.33x |
| 2026-01-14 | 6.28x |
| 2026-01-13 | 6.23x |
| 2026-01-12 | 6.32x |
| 2026-01-09 | 6.41x |
| 2026-01-08 | 6.41x |
| 2026-01-07 | 6.42x |
| 2026-01-06 | 6.40x |
| 2026-01-05 | 6.12x |
| 2026-01-02 | 6.11x |
| 2025-12-31 | 6.16x |
| 2025-12-30 | 6.20x |
| 2025-12-29 | 6.18x |
| 2025-12-26 | 6.20x |
| 2025-12-24 | 6.21x |
| 2025-12-23 | 6.21x |
| 2025-12-22 | 6.24x |
| 2025-12-19 | 6.22x |
| 2025-12-18 | 6.19x |
| 2025-12-17 | 6.18x |
| 2025-12-16 | 6.16x |
| 2025-12-15 | 6.22x |
| 2025-12-12 | 6.20x |
| 2025-12-11 | 6.18x |
| 2025-12-10 | 6.20x |
| 2025-12-09 | 6.12x |
| 2025-12-08 | 6.19x |
| 2025-12-05 | 6.36x |
| 2025-12-04 | 6.36x |
| 2025-12-03 | 6.39x |
| 2025-12-02 | 6.40x |
| 2025-12-01 | 6.49x |
| 2025-11-28 | 6.47x |
| 2025-11-26 | 6.49x |
| 2025-11-25 | 6.53x |
| 2025-11-24 | 6.46x |
| 2025-11-21 | 6.43x |
| 2025-11-20 | 6.30x |
| 2025-11-19 | 6.36x |
| 2025-11-18 | 6.29x |
| 2025-11-17 | 6.30x |
| 2025-11-14 | 6.33x |
| 2025-11-13 | 6.51x |
| 2025-11-12 | 6.41x |
| 2025-11-11 | 6.35x |
| 2025-11-10 | 6.22x |
| 2025-11-07 | 6.23x |
| 2025-11-06 | 6.20x |
| 2025-11-05 | 6.26x |
| 2025-11-04 | 6.34x |
| 2025-11-03 | 6.27x |
| 2025-10-31 | 6.23x |
| 2025-10-30 | 6.61x |
| 2025-10-29 | 6.62x |
| 2025-10-28 | 6.72x |
| 2025-10-27 | 6.84x |
| 2025-10-24 | 6.81x |
| 2025-10-23 | 6.83x |
| 2025-10-22 | 6.92x |
| 2025-10-21 | 6.78x |
| 2025-10-20 | 6.80x |
| 2025-10-17 | 6.69x |
| 2025-10-16 | 6.61x |
| 2025-10-15 | 6.62x |
| 2025-10-14 | 6.62x |
| 2025-10-13 | 6.54x |
| 2025-10-10 | 6.53x |
| 2025-10-09 | 6.63x |
| 2025-10-08 | 6.71x |
| 2025-10-07 | 6.61x |
| 2025-10-06 | 6.56x |
| 2025-10-03 | 6.63x |
| 2025-10-02 | 6.56x |
| 2025-10-01 | 6.53x |
| 2025-09-30 | 6.62x |
| 2025-09-29 | 6.62x |
| 2025-09-26 | 6.61x |
| 2025-09-25 | 6.60x |
| 2025-09-24 | 6.64x |
| 2025-09-23 | 6.68x |
| 2025-09-22 | 6.76x |
| 2025-09-19 | 6.73x |
| 2025-09-18 | 6.75x |
| 2025-09-17 | 6.73x |
| 2025-09-16 | 6.73x |
| 2025-09-15 | 6.74x |
| 2025-09-12 | 6.84x |
| 2025-09-11 | 6.93x |
| 2025-09-10 | 6.83x |
| 2025-09-09 | 6.99x |
| 2025-09-08 | 7.00x |
| 2025-09-05 | 6.98x |
| 2025-09-04 | 7.02x |
| 2025-09-03 | 6.92x |
| 2025-09-02 | 6.95x |
| 2025-08-29 | 6.97x |
| 2025-08-28 | 6.94x |
| 2025-08-27 | 7.00x |
| 2025-08-26 | 7.02x |
| 2025-08-25 | 6.96x |
| 2025-08-22 | 7.01x |
| 2025-08-21 | 6.86x |
| 2025-08-20 | 6.98x |
| 2025-08-19 | 6.95x |
| 2025-08-18 | 6.81x |
| 2025-08-15 | 6.82x |
| 2025-08-14 | 6.76x |
| 2025-08-13 | 6.77x |
| 2025-08-12 | 6.73x |
| 2025-08-11 | 6.73x |
| 2025-08-08 | 6.74x |
| 2025-08-07 | 6.73x |
| 2025-08-06 | 6.70x |
| 2025-08-05 | 6.80x |
| 2025-08-04 | 6.81x |
| 2025-08-01 | 6.75x |
| 2025-07-31 | 7.18x |
| 2025-07-30 | 7.31x |
| 2025-07-29 | 7.31x |
| 2025-07-28 | 7.32x |
| 2025-07-25 | 7.36x |
| 2025-07-24 | 7.25x |
| 2025-07-23 | 7.32x |
| 2025-07-22 | 7.22x |
| 2025-07-21 | 7.09x |
| 2025-07-18 | 7.13x |
| 2025-07-17 | 7.12x |
| 2025-07-16 | 7.15x |
| 2025-07-15 | 7.15x |
| 2025-07-14 | 7.16x |
| 2025-07-11 | 7.13x |
| 2025-07-10 | 7.22x |
| 2025-07-09 | 7.17x |
| 2025-07-08 | 7.13x |
| 2025-07-07 | 7.18x |
| 2025-07-03 | 7.23x |
| 2025-07-02 | 7.17x |
| 2025-07-01 | 7.25x |
| 2025-06-30 | 7.23x |
| 2025-06-27 | 7.20x |
| 2025-06-26 | 7.14x |
| 2025-06-25 | 7.18x |
| 2025-06-24 | 7.08x |
| 2025-06-23 | 6.96x |
| 2025-06-20 | 6.90x |
| 2025-06-18 | 6.86x |
| 2025-06-17 | 6.86x |
| 2025-06-16 | 6.92x |
| 2025-06-13 | 6.93x |
| 2025-06-12 | 6.98x |
| 2025-06-11 | 6.99x |
| 2025-06-10 | 7.06x |
| 2025-06-09 | 7.01x |
| 2025-06-06 | 7.04x |
| 2025-06-05 | 7.02x |
| 2025-06-04 | 7.01x |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
Related Metrics
About Stryker Corporation
Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Kevin A. Lobo